Glyburide and Metformin (Glucovance)

FDA has contraindicated the concomitant administration of Bosentan and Colesevelam with Glucovance.

Glyburide a sulfonylurea lowers blood glucose levels by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets.

Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

Bosentan is an orally active competitive inhibitor of endothelin used for pulmonary arterial hypertension.

Colesevelam is a bile acid binding resin useful only for isolated increases in LDL.

Recommendations:

Concomitant use of these drugs can lead to an increased risk of liver enzyme elevations.

Glucovance should be administered at least 4 hours prior to Colesevelam as their concomitant administration reduces maximum plasma concentration and total exposure to glyburide.

http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm194334.htm

Lexiscan (regadenoson) and Adenoscan (adenosine): Drug Safety Communication - Rare but Serious Risk of Heart Attack and Death

1. Screen all nuclear stress test candidates for their suitability to receive Lexiscan or Adenoscan. 
2. Avoid using these drugs in patients with signs or symptoms of unstable angina or cardiovascular instability, as these patients may be at greater risk for serious cardiovascular adverse reactions. 
3. Cardiac resuscitation equipment and trained staff should be available before administering Lexiscan or Adenoscan.http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm375981.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery